Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
Chim Chor, Lie, Chan, Liu, Lau Ching, Yip Sze, Sim Joycelyn, Wan Thomas, Ma Edmond, Liang Raymond, Tse Eric, Kwong Yok-Lam, For